On 1 August 2023, Novasight Hybrid Catheter (Certificate No. 20233060333), a medical technology product of Grand Pharmaceutical Group Limited (Stock Code: 00512.HK), obtained the import drug license. The Novasight Hybrid System endovascular imaging device was approved for marketing by National Medical Products Administration on 16 May this year. Since then, the innovative IVUS+OCT dual-mode imaging system (devices and catheters) for coronary artery intravascular imaging can be formally applied to PCI diagnosis and treatment, which benefits a wide range of patients.

Grandpharma Medical Device (GMD), part of Grand Pharmaceutical Group, has been deeply engaged in the field of cardiovascular and cerebrovascular precision interventional diagnosis and treatment over the years. Following the principle of “intervention without implantation”, our Group has built up a cluster of advanced medical devices with an integrated layout focusing on access management, structural heart disease, electrophysiology and heart failure.

Currently, GMD of Grand Pharmaceutical Group has launched sixteen products. In the vascular intervention field, seven products have been launched in China. Our Group has achieved the comprehensive construction of innovative medical device platform, and established a network of two centres in China and multiple bases overseas for research, development and production. Our Group is committed to building a leading cardiovascular and cerebrovascular precision interventional diagnostic platform across China and the world. The Novasight system is an important part of our Group’s core strategy field, cardiovascular and cerebrovascular precision interventional diagnosis and treatment.